Results of a clinical trial with bromperidol C-C 2489/21.

Abstract

A controlled clinical study--phase III--with bromperidol was conducted on 30 male patients with a diagnosis of schizophrenia of different subtypes, realized by psychiatric assessments and by laboratory measures over an eight-week investigational period. A global improvement (from very much up to moderately) was achieved in 76% of the patients; two patients dropped out. The optimal dosage of bromperidol seemed to lie between 4 and 6 mg/day. The adverse effects were confined to moderate extrapyramidal symptoms in the extent of a higher dosage. Bromperidol appears to be a potent longacting neuroleptic drug without essential psychomotor damping, anxiolytic and hypnosedating properties, but with a strong antipsychotic potential against the basic schizophrenic disintegration. It is mainly indicated in paranoia, depressive-paranoia and simple forms of schizophrenia.

• Authors: G Weiser
• Journal: Acta psychiatrica Belgica (Acta Psychiatr Belg) 1978 Jan-Feb Vol. 78 Issue 1 Pg. 102-9 ISSN: 0300-8967 [Print] Belgium
• PMID: 347873 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Haloperidol

Topics

• Adolescent
• Adult
• Akathisia, Drug-Induced
• Clinical Trials as Topic
• Drug Evaluation
• Haloperidol (adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Male
• Middle Aged
• Psychiatric Status Rating Scales
• Schizophrenia (drug therapy)